Catabolic and anabolic actions of parathyroid hormone on the skeleton

Journal of Endocrinological Investigation

Volumn 34, Issue 10, 2011, Pages 801-810

  Silva, B C ^a   Costa, A G ^a   Cusano, N E ^a   Kousteni, S ^a   Bilezikian, J P ^a  

^a Columbia University ^*  (United States)

Author keywords

Hyperparathyroidism; Osteoblastogenesis; Osteoclastogenesis; PTH; PTH(1 84); Teriparatide

Indexed keywords

PARATHYROID HORMONE; SCLEROSTIN; SOMATOMEDIN C;

BIOSYNTHESIS; BONE DENSITY; BONE DEVELOPMENT; BONE METABOLISM; BONE MINERALIZATION; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; CANCELLOUS BONE; CATABOLISM; CORTICAL BONE; FRACTURE; HORMONAL THERAPY; HORMONE ACTION; HORMONE PROTEIN COMPLEX; HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; REVIEW; RISK REDUCTION;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE REMODELING; BONE RESORPTION; FEMALE; FRACTURES, BONE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RANK LIGAND; RISK; TERIPARATIDE;

EID: 84856902222     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7925     Document Type: Review

References (109)

1. Hanley DA, Watson PH, Hodsman AB, Dempster DW. Pharmacological Mechanisms of Therapeutics: Parathyroid Hormone. In: Bilezikian J, Raisz LG, Martin TJ (eds). Principles of Bone Biology. Amsterdam: Elsevier. 2008, 1661-95.
2. Datta NS, Abou-Samra AB. PTH and PTHrP signaling in osteoblasts. Cell Signal 2009, 21: 1245-54.
3. Kousteni S, Bilezikian JP. The cell biology of parathyroid hormone in osteoblasts. Curr Osteoporos Rep 2008, 6: 72-6.
4. Potts JT. Parathyroid hormone: past and present. J Endocrinol 2005, 187: 311-25. (Pubitemid 43020252)
5. Datta NS, Samra TA, Mahalingam CD, Datta T, Abou-Samra AB. Role of PTH1R internalization in osteoblasts and bone mass using a phosphorylation-deficient knock-in mouse model. J Endocrinol 2010, 207: 355-65.
6. Kramer I, Keller H, Leupin O, Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab 2010, 21: 237-44.
7. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989, 4: 283-91. (Pubitemid 19161996)
8. Dempster DW, Muller R, Zhou H, et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone 2007, 41: 19-24. (Pubitemid 46891902)
9. Parisien M, Mellish RW, Silverberg SJ, et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res 1992, 7: 913-9.
10. Parisien M, Silverberg SJ, Shane E, et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 1990, 70: 930-8.
11. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997, 138: 4607-12. (Pubitemid 27460894)
12. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344: 1434-41. (Pubitemid 32402100)
13. Greenspan SL, Bone HG, Ettinger MP, et al; Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007, 146: 326-39. (Pubitemid 351650593)
14. Onyia JE, Helvering LM, Gelbert L, et al. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J Cell Biochem 2005, 95: 403-18. (Pubitemid 41420208)
15. Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 2003, 89: 180-90. (Pubitemid 36459108)
16. Cope O. The study of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med 1966, 274: 1174-82.
17. Dauphine RT, Riggs BL, Scholz DA. Back pain and vertebral crush fractures: an unemphasized mode of presentation for primary hyperparathyroidism. Ann Intern Med 1975, 83: 365-7.
18. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008, 93: 3462-70.
19. rd, Hodgson SF, Kennedy MA. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med 1980, 302: 189-93. (Pubitemid 10212006)
20. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999, 341: 1249-55. (Pubitemid 29489739)
21. Parisien M, Cosman F, Mellish RW, et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res 1995, 10: 1393-9.
22. Uchiyama T, Tanizawa T, Ito A, Endo N, Takahashi HE. Microstructure of the trabecule and cortex of iliac bone in primary hyperparathyroidism patients determined using histomorphometry and node-strut analysis. J Bone Miner Metab 1999, 17: 283-8.
23. Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab 1996, 81: 4007-12. (Pubitemid 26380410)
24. Hansen S, Beck Jensen JE, Rasmussen L, Hauge EM, Brixen K. Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: A case-control study using HR-pQCT. J Bone Miner Res 2010, 25: 1941-7.
25. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005, 257: 6-17. (Pubitemid 40129122)
26. Kulak CA, Bandeira C, Voss D, et al. Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. J Clin Endocrinol Metab 1998, 83: 732-5. (Pubitemid 28496437)
27. Yu N, Donnan PT, Flynn RW, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) 2010, 73: 30-4.
28. rd, Wermers RA, Crowson CS, O'Fallon W, Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999, 14: 1700-7. (Pubitemid 29455818)
29. Vignali E, Viccica G, Diacinti D, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94: 2306-12.
30. Wilson RJ, Rao S, Ellis B, Kleerekoper M, Parfitt AM. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988, 109: 959-62. (Pubitemid 19046064)
31. rd. Risk of age-related fractures in patients with primary hyperparathyroidism. Arch Intern Med 1992, 152: 2269-73.
32. Larsson K, Ljunghall S, Krusemo UB, Naessén T, Lindh E, Persson I. The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Intern Med 1993, 234: 585-93. (Pubitemid 24010361)
33. Parfitt AM. Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002, 17: 1741-3.
34. Bilezikian JP. Bone strength in primary hyperparathyroidism. Osteoporos Int 2003, 14 (Suppl 5): S113-5.
35. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001, 16: 157-65. (Pubitemid 32046201)
36. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16: 1846-53. (Pubitemid 32911491)
37. Recker RR, Bare SP, Smith SY, et al. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84. Bone 2009, 44: 113-9.
38. Ma YL, Zeng Q, Donley DW, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 2006, 21: 855-64. (Pubitemid 43787992)
39. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18: 1932-41. (Pubitemid 37377441)
40. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18: 9-17. (Pubitemid 36008334)
41. Fox J, Miller MA, Recker RR, Bare SP, Smith SY, Moreau I. Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 2005, 5: 356-7.
42. Dobnig H, Sipos A, Jiang Y, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005, 90: 3970-7. (Pubitemid 41058159)
43. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2000, 11: 434-42. (Pubitemid 30450127)
44. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85: 3069-76.
45. Rubin MR, Bilezikian JP. Parathyroid hormone as an anabolic skeletal therapy. Drugs 2005, 65: 2481-98. (Pubitemid 41697316)
46. Lindsay R, Cosman F, Zhou H, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006, 21: 366-73.
47. Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 2007, 40: 1447-52. (Pubitemid 46756408)
48. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007, 22: 495-502. (Pubitemid 47457425)
49. Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18: 539-43.
50. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354: 2250-61.
51. Chambers TJ, Fuller K, McSheehy PM, Pringle JA. The effects of calcium regulating hormones on bone resorption by isolated human osteoclastoma cells. J Pathol 1985, 145: 297-305. (Pubitemid 15033383)
52. McSheehy PM, Chambers TJ. Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 1986, 118: 824-8. (Pubitemid 16162808)
53. Kaji H, Sugimoto T, Kanatani M, Fukase M, Chihara K. Involvement of dual signal transduction systems in the stimulation of osteoclast-like cell formation by parathyroid hormone and parathyroid hormone-related peptide. Biochem Biophys Res Commun 1993, 194: 157-62. (Pubitemid 23237914)
54. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999, 140: 3552-61. (Pubitemid 30645409)
55. Ma YL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001, 142: 4047-54. (Pubitemid 32802678)
56. Kanzawa M, Sugimoto T, Kanatani M, Chihara K. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. Eur J Endocrinol 2000, 142: 661-4. (Pubitemid 30399499)
57. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008, 29: 155-92. (Pubitemid 351519689)
58. Huang JC, Sakata T, Pfleger LL, et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 2004, 19: 235-44. (Pubitemid 38116737)
59. Fu Q, Jilka RL, Manolagas SC, O'Brien CA. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 2002, 277: 48868-75. (Pubitemid 35470855)
60. Nakchbandi IA, Lang R, Kinder B, Insogna KL. The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J Clin Endocrinol Metab 2008, 93: 967-73. (Pubitemid 351398581)
61. Stilgren LS, Rettmer E, Eriksen EF, Hegedüs L, Beck-Nielsen H, Abrahamsen B. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone 2004, 35: 256-65. (Pubitemid 38789173)
62. Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J Biol Chem 2007, 282: 33098-106. (Pubitemid 350159306)
63. Langub MC, Monier-Faugere MC, Qi Q, Geng Z, Koszewski NJ, Malluche HH. Parathyroid hormone/parathyroid hormone-related peptide type 1 receptor in human bone. J Bone Miner Res 2001, 16: 448-56. (Pubitemid 32173359)
64. Dempster DW, Hughes-Begos CE, Plavetic-Chee K, et al. Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J Cell Biochem 2005, 95: 139-48. (Pubitemid 41420224)
65. Shen V, Dempster DW, Birchman R, Xu R, Lindsay R. Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J Clin Invest 1993, 91: 2479-87. (Pubitemid 23182499)
66. Wronski TJ, Yen CF, Qi H, Dann LM. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 1993, 132: 823-31. (Pubitemid 23056145)
67. Iwaniec UT, Moore K, Rivera MF, Myers SE, Vanegas SM, Wronski TJ. A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos Int 2007, 18: 351-62. (Pubitemid 46233181)
68. Yang D, Singh R, Divieti P, Guo J, Bouxsein ML, Bringhurst FR. Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone. Bone 2007, 40: 1453-61. (Pubitemid 46779002)
69. Ogata N, Shinoda Y, Wettschureck N, et al. G alpha(q) signal in osteoblasts is inhibitory to the osteoanabolic action of parathyroid hormone. J Biol Chem 2011, 286: 13733-40.
70. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007, 40: 1434-46. (Pubitemid 46756429)
71. Kousteni S, Bilezikian J. Cellular Actions of Parathyroid Hormone. In: Bilezikian J, Raisz LG, Martin TJ (eds). Principles of Bone Biology. Amsterdam: Elsevier. 2008, 639-56.
72. Wang YH, Liu Y, Rowe DW. Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures. Am J Physiol Endocrinol Metab 2007, 292: E594-603. (Pubitemid 46220585)
73. Qin L, Li X, Ko JK, Partridge NC. Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J Biol Chem 2005, 280: 3104-11. (Pubitemid 40189421)
74. Onishi T, Hruska K. Expression of p27Kip1 in osteoblast-like cells during differentiation with parathyroid hormone. Endocrinology 1997, 138: 1995-2004. (Pubitemid 27180818)
75. Datta NS, Kolailat R, Fite A, Pettway G, Abou-Samra AB. Distinct roles for mitogen-activated protein kinase phosphatase-1 (MKP-1) and ERK-MAPK in PTH1R signaling during osteoblast proliferation and differentiation. Cell Signal 2010, 22: 457-66.
76. Datta NS, Pettway GJ, Chen C, Koh AJ, McCauley LK. Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res 2007, 22: 951-64. (Pubitemid 351339717)
77. Ogita M, Rached MT, Dworakowski E, Bilezikian JP, Kousteni S. Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration. Endocrinology 2008, 149: 5713-23.
78. Ishizuya T, Yokose S, Hori M, et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 1997, 99: 2961-70. (Pubitemid 27278673)
79. Chen HL, Demiralp B, Schneider A, et al. Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem 2002, 277: 19374-81. (Pubitemid 34967444)
80. Krishnan V, Moore TL, Ma YL, et al. Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol Endocrinol 2003, 17: 423-35. (Pubitemid 36315636)
81. Hisa I, Inoue Y, Hendy GN, et al. Parathyroid hormone-responsive Smad3-related factor, Tmem119, promotes osteoblast differentiation and interacts with the bone morphogenetic protein-Runx2 pathway. J Biol Chem 2011, 286: 9787-96.
82. Pettway GJ, Schneider A, Koh AJ, et al. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. Bone 2005, 36: 959-70. (Pubitemid 40797996)
83. Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003, 278: 50259-72. (Pubitemid 37548867)
84. Schnoke M, Midura SB, Midura RJ. Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair. Bone 2009, 45: 590-602.
85. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005, 19: 1842-4. (Pubitemid 41598769)
86. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10: 537-43. (Pubitemid 32184286)
87. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002, 39: 91-7. (Pubitemid 34146376)
88. Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005, 15: 928-35. (Pubitemid 40994212)
89. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008, 23: 860-9. (Pubitemid 351768804)
90. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24: 578-88.
91. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26: 19-26.
92. Fermor B, Skerry TM. PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J Bone Miner Res 1995, 10: 1935-43.
93. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146: 4577-83. (Pubitemid 41446595)
94. Rhee Y, Allen MR, Condon K, et al. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res 2011, 26: 1035-46.
95. Drake MT, Srinivasan B, Mödder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010, 95: 5056-62.
96. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone 2005, 37: 148-58. (Pubitemid 40962421)
97. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010, 95: 1991-7.
98. van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 2010, 163: 833-7.
99. Costa A, Cremers S, Rubin M, et al. Circulating Sclerostin Levels in Disorders of Parathyroid Function: Primary Hyperparathyroidism (PHPT) and Hypoparathyroidism (HypoPT). ASBMR 2010 Annual Meeting 2010: S158 (abstract).
100. Semënov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005, 280: 26770-5.
101. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005, 280: 19883-7. (Pubitemid 41379516)
102. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135: 825-37.
103. Wang Y, Nishida S, Boudignon BM, et al. IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res 2007, 22: 1329-37. (Pubitemid 351339678)
104. Lombardi G, Di Somma C, Vuolo L, Guerra E, Scarano E, Colao A. Role of IGF-I on PTH effects on bone. J Endocrinol Invest 2010, 33 (7 Suppl): 22-6.
105. Yakar S, Bouxsein ML, Canalis E, et al. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol 2006, 189: 289-99.
106. Yamaguchi M, Ogata N, Shinoda Y, et al. Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology 2005, 146: 2620-8. (Pubitemid 40695564)
107. Pacifici R. T cells: critical bone regulators in health and disease. Bone 2010, 47: 461-71.
108. Gao Y, Wu X, Terauchi M, et al. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab 2008, 8: 132-45.
109. Tawfeek H, Bedi B, Li JY, et al. Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One 2010, 5: e12290.